- Home
- TVTX
as 02-21-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.8B | IPO Year: | N/A |
| Target Price: | $30.08 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $25.29 | Next Earning Date: | 02-20-2025 |
| Revenue: | $233,175,000 | Revenue Growth: | 60.55% |
| Revenue Growth (this year): | 62.88% | Revenue Growth (next year): | 57.60% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Feb 10 '25 | Sell | $23.53 | 5,200 | $122,356.00 | 98,519 | |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Feb 10 '25 | Sell | $23.53 | 8,000 | $188,240.00 | 89,482 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Feb 10 '25 | Sell | $24.27 | 5,642 | $137,275.55 | 127,634 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 10 '25 | Sell | $23.53 | 2,568 | $60,425.55 | 89,602 | |
| Baynes Roy D. | TVTX | Director | Feb 6 '25 | Sell | $22.00 | 10,000 | $220,000.00 | 31,000 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Jan 31 '25 | Sell | $20.21 | 50,691 | $1,024,343.45 | 430,548 | |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Jan 31 '25 | Sell | $19.78 | 8,951 | $177,050.78 | 98,519 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Jan 31 '25 | Sell | $20.12 | 3,348 | $67,361.76 | 63,654 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Jan 31 '25 | Sell | $20.12 | 5,166 | $103,939.92 | 127,634 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Jan 31 '25 | Sell | $20.12 | 5,192 | $104,463.04 | 90,038 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
2 days ago
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings
Insider Monkey
8 days ago
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
GlobeNewswire
9 days ago
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
TipRanks
9 days ago
Travere Therapeutics price target raised to $32 from $27 at Scotiabank
GlobeNewswire
10 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
11 days ago
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Simply Wall St.
12 days ago
Exploring 3 High Growth Tech Stocks in the United States
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.